Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial

JAMA: The Journal of the American Medical Association

Volumn 273, Issue 12, 1995, Pages 934-941

  Abraham, Edward ^a   Wunderink, Richard ^b   Silverman, Henry ^c   Perl, Trish M ^d   Wenzel, Richard P ^d   Nasraway, Stanley ^e   Levy, Howard ^f   Balk, Robert ^g   Allred, Randy ^h   Pennington, James E ^h   Wherry, Janice C ^h   Bone, Roger ⁱ  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h BAYER AG   (Germany)

ⁱ MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOTOXIN; MONOCLONAL ANTIBODY; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL CARE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SERUM SICKNESS; SYNDROME;

EID: 0028957549     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1995.03520360048038     Document Type: Article

References (41)

1. Wenzel RP. Anti-endotoxin monoclonal antibodies: a second look. N Engl J Med. 1992;326:1151-1153.
2. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Ann Intern Med. 1990;113: 227-242.
3. Young LS. Gram-negative sepsis. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. 3rd ed. New York, NY: Churchill Livingstone Inc; 1990:611-636.
4. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
5. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317:659-665.
6. Ispahani P, Pearson NJ, Greenwood D. An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. Q J Med. 1987;63:427-440.
7. The HA-1A Sepsis Study Group. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind placebo-controlled trial. N Engl J Med. 1991;324:429-436.
8. Parrillo JE, Management of septic shock: present and future. Ann Intern Med. 1991;115:491-493.
9. Bone RC, Fisher CJ Jr, Clemmer TP, et al. Sepsis syndrome: a valid clinical entity. Crit Care Med. 1989;17:389-393.
10. Selby P, Hobbs S, Viner C, Jackson E, et al. Tumor necrosis factor in man: clinical and biological observations. Br J Cancer. 1987;56:803-808.
11. Sherman ML, Spriggs DR, Arthur KA, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988;6:344-350.
12. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-1951.
13. Van der Poll T, Buller HR, ten Cate HT. Activation of coagulation after administration of TNF to normal subjects. N Engl J Med. 1990;322:1622-1627.
14. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318: 1481-1486.
15. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating IL-1 and TNF in septic shock and experimental endotoxin fever. J Infect Dis. 1990;161: 79-84.
16. Tracey KJ, Fong Y, Hesse DG, et al. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987; 330:662-664.
17. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/TNF reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J Exp Med. 1989;170:1627-1633.
18. Opal SM, Cross AS, Kelly NM, et al. Efficacy of a monoclonal antibody directed against TNF in protecting neutropenic rats from lethal infection with P. aeruginosa. J Infect Dis. 1990;161:1148-1152.
19. Hinshaw LB, Tekamp-Olson P, Chang AC, et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circ Shock. 1990;30:279-292.
20. Lindsey DC, Jesmok GJ, Duerr ML, et al. Dose dependent protection by TNF-alpha monoclonal antibody (TNF MAb) after a LD100 E. coli challenge in pigs. Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 30, 1991; Chicago, Ill. Abstract 537.
21. Duerr ML, Valdez CM, Emerson TE, et al. Serum kinetics of cytokines after TNF-alpha monoclonal antibody (TNF MAb) treatment in gram-negative and positive bacteremic baboon models. Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 30, Chicago, Ill. Abstract 538.
22. Collins MS, Mehton NS, Hector RF, et al. Treatment of acute peritonitis in young swine with gentamicin and a monoclonal antibody against tumor necrosis factor. Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; October 1,1991; Chicago, Ill. Abstract 540.
23. Jesmok GJ, Lindsey DC, Fournel MA, Emerson TE. Possible mechanisms of protection afforded by tumor necrosis factor monoclonal antibody (TNF MAb) in E. coli challenged pigs. Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 30, 1991; Chicago, Ill. Abstract 84.
24. Walsh CJ, Sugerman HJ, Mullen PG, et al. Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis. Arch Surg. 1992;127:138-144.
25. Jesmok GJ, Lindsey DC, Duerr ML, Fournel MA, Emerson TE Jr. Efficacy of monoclonal antibody against human recombinant TNF in E. coli challenged swine. Am J Pathol. 1992;141:1197-1207.
26. Fiedler VB, Ingo L, Sander E, Voehringer V, Galanos C, Fournel M. Monoclonal antibody to tumor necrosis factor—α prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med. 1992;120:574-588.
27. Schlag G, Redl H, Davies J. TNF-Antibodies (CB 0006) in a subchronic septic model in baboons to prevent multi-organ failure (MOF). Presented at the Second International Conference on Shock; June 4, 1991; Vienna, Austria. Abstract 460.
28. Emerson TE Jr, Lindsey DC, Jesmok GJ, Duerr ML, Fournel MA. Efficacy of monoclonal antibody against tumor necrosis factor alpha in a low mortality endotoxemic baboon model. Circ Shock. 1992; 38:775-784.
29. Hinshaw LB, Emerson TE Jr, Taylor FB Jr, et al. Lethal S. aureus shock in primates: prevention of death with anti-TNF antibody. J Trauma. 1992; 33:568-573.
30. Walsh C, Sugerman H, Mullen P, et al. Monoclonal antibody to tumor necrosis factor improves the course of septic lung injury. Presented at the 17th International Congress of Chemotherapy; June 26, 1991; Berlin, Germany. Abstract 863.
31. Saravolatz LD, Wherry JC, Spooner C, et al. Clinical safety, tolerability and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor alpha. J Infect Dis. 1994;169:214-217.
32. Galloway CJ, Madanat MS, Mitra G. Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity. J Immunol Methods. 1991;140:37-43.
33. Pauli U, Bertoni G, Duerr M, Peterhans E. A bioassay for the detection of tumor necrosis factor from eight different species: evaluation of neutralization rates of a monoclonal antibody against human TNF-α. J Immunol Methods. 1994;171:263-265.
34. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-828.
35. Tran DD, Groenveld ABJ, Meulen JVD, Nauta JJP, Strack van Schijndel RJM, Thijs LG. Age, chronic disease, sepsis, organ system failure and mortality in a medical intensive care unit. Crit Care. 1990;18:474-479.
36. O'Brien PC. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
37. Fisher CJ Jr, Dhainaut J-F, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA. 1994;271:1836-1843 Correction: 1994;272:1170.
38. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991;266:1097-1102.
39. Havell EA. Evidence that TNF has an important role in antibacterial resistance. J Immunol. 1989;143:2894-2899.
40. Tompkins RG. Human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome. Crit Care Med. 1994;22:3.
41. Luce JM. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med. 1993;21:1233-1241.